Pulse Biosciences, Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>Pulse Biosciences, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to elect directors and ratify auditors.</b>

AI Summary

Pulse Biosciences, Inc. (PLSE) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Annual meeting to be held virtually via live audio webcast on June 6, 2024, at 8:00 a.m. Pacific Time. Stockholders will vote on the election of five directors and the ratification of Deloitte & Touche LLP as independent auditors. Proxy materials will be accessible online via a Notice of Internet Availability. The company will report on operations and outlook for the year ahead. Stockholders can vote and submit questions during the meeting at www.virtualshareholdermeeting.com/PLSE2024.

Why It Matters

For investors and stakeholders tracking Pulse Biosciences, Inc., this filing contains several important signals. This filing is a definitive proxy statement (DEF 14A) detailing the agenda and voting procedures for the upcoming annual meeting. The virtual format allows for broader participation and accessibility for stockholders to engage with company management and vote on key proposals.

Risk Assessment

Risk Level: — Pulse Biosciences, Inc. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks disclosed.

Analyst Insight

Stockholders should review the proxy materials to make informed voting decisions on director elections and auditor ratification.

Key Numbers

• June 6, 2024 — Annual Meeting Date (Date of the 2024 Annual Meeting of Stockholders)
• 8:00 a.m. — Meeting Time (Time of the Annual Meeting (Pacific Time))
• 5 — Directors to Elect (Number of directors to be elected at the meeting)

Key Players & Entities

• Pulse Biosciences, Inc. (company) — Registrant and company name
• Deloitte & Touche LLP (company) — Independent auditors
• June 6, 2024 (date) — Date of the Annual Meeting
• 2024 (date) — Year of the Annual Meeting
• 2025 (date) — Year for director terms
• 5 (dollar_amount) — Number of directors to be elected

FAQ

Risk Factors

• Proxy Statement Filing [low — regulatory]: The filing is a routine DEF 14A proxy statement, indicating compliance with SEC disclosure requirements for annual meetings.

Industry Context

Pulse Biosciences operates in the medical instruments and apparatus industry, focusing on surgical and medical devices.

Regulatory Implications

The filing adheres to Section 14(a) of the Securities Exchange Act of 1934 and related SEC rules governing proxy solicitations.

What Investors Should Do

1. Review the list of director nominees and their qualifications.
2. Evaluate the appointment of Deloitte & Touche LLP as independent auditors.
3. Understand the virtual meeting procedures for voting and asking questions.

Key Dates

• 2024-06-06: Annual Meeting of Stockholders — Key date for voting on proposals and company updates.
• 2024-04-23: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (Provides detailed information about matters to be voted on at a company's annual meeting.)

Notice of Internet Availability of Proxy Materials

A notice sent to stockholders informing them how to access proxy materials online. (Facilitates electronic delivery of proxy materials, reducing printing and mailing costs.)

Year-Over-Year Comparison

This is the initial filing for the 2024 annual meeting proxy statement.

Filing Documents

• plse20240417_def14a.htm (DEF 14A) — 616KB
• image01.jpg (GRAPHIC) — 8KB
• prxy_page1.jpg (GRAPHIC) — 128KB
• prxy_page2.jpg (GRAPHIC) — 129KB
• 0001437749-24-012863.txt (&nbsp;) — 983KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15 EXECUTIVE OFFICERS 16

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 17 Compensation Committee Report 17 Overview of Compensation Program 17

Executive Compensation

Executive Compensation 17 Summary Compensation Table 18 Outstanding Equity Awards at Fiscal Year-End 19 Pay Versus Performance 19 Executive Officer Employment Agreements 21 Equity Compensation Plan Information 23 AUDIT COMMITTEE REPORT 24 OTHER INFORMATION 25 Section 16(a) Beneficial Ownership Reporting Compliance 25 Stockholder Proposals 25 Stockholders Sharing the Same Address 25 Fiscal Year 2023 Annual Report and SEC Filings 25 Notice and Access 26 -ii- PULSE BIOSCIENCES, INC. PROXY STATEMENT FOR THE ANNUAL MEETING OF STOCKHOLDERS To Be Held at 8:00 a.m., Pacific Time, on June 6 , 2024 G ENERAL INFORMATION We are providing you with this Proxy Statement and the enclosed form of proxy in connection with the solicitation by our Board of Directors for use at our 2024 annual meeting of stockholders (the "Annual Meeting"). The Annual Meeting will be conducted virtually via live audio webcast by visiting www.virtualshareholdermeeting.com/PLSE2024 on June 6, 2024 at 8:00 a.m., Pacific Time. This Proxy Statement contains important information regarding our Annual Meeting, the proposals on which you are being asked to vote, information you may find useful in determining how to vote, and information about our voting procedures. As used herein, the terms "we," "us," "our," "Pulse Biosciences," and the "Company" all refer to Pulse Biosciences, Inc., a Delaware corporation. This Proxy Statement and the accompanying proxy card or voting instruction form will first be made available to our stockholders on or about April 25, 2024. See the section entitled "Fiscal Year 2023 Annual Report and SEC Filings" for information on accessing our 2023 Annual Report to Stockholders. The information provided in the "question and answer" format below is for your convenience only and is merely a summary of the information contained in this Proxy Statement. You should read this entire Proxy Statement carefully. Information contained on, or tha

View Full Filing

View this DEF 14A filing on SEC EDGAR